Annual report
3154.TEDINET S100Z48T
Period2025-07-01 → 2026-06-30
Filed2026-09-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥302.3bn | 2025-07-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥288.7bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥259.8bn | 2023-07-01 → 2024-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥239.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥226.6bn | 2021-07-01 → 2022-06-30v | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2025-07-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2024-07-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2025-07-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-07-01 → 2024-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2022-07-01 → 2023-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2021-07-01 → 2022-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2025-07-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2024-07-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥944m | 2025-07-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2023-07-01 → 2024-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.5bn | 2022-07-01 → 2023-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2021-07-01 → 2022-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥944m | 2025-07-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥112.6bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥113.0bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥114.8bn | at 2024-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥97.5bn | at 2023-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥93.0bn | at 2022-06-30v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥91.8bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥92.5bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥20.7bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥20.5bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥19.7bn | at 2024-06-30v | Cons. | Net assets |
| Net assets / equity | ¥18.6bn | at 2023-06-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥17.3bn | at 2022-06-30v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.1bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.3bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.0bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.5bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.3bn | at 2023-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥9.1bn | at 2022-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥374m | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.0bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥3.9bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.5bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥863m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.4bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.5bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.0bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥863m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥5.2bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥42.45 | 2025-07-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.91 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.21 | 2023-07-01 → 2024-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.32 | 2022-07-01 → 2023-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.3 | 2021-07-01 → 2022-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥42.38 | 2025-07-01 → 2026-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.85 | 2024-07-01 → 2025-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥51 | 2023-07-01 → 2024-06-30v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.09 | 2022-07-01 → 2023-06-30v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.15 | 2021-07-01 → 2022-06-30v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥932.55 | at 2026-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥920.89 | at 2025-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥891.21 | at 2024-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥847.1 | at 2023-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥789.43 | at 2022-06-30v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 18.4% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.2% | at 2024-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.1% | at 2023-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.6% | at 2022-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2025-07-01 → 2026-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2024-07-01 → 2025-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2023-07-01 → 2024-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2022-07-01 → 2023-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2021-07-01 → 2022-06-30v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,716 | at 2026-06-30 | Cons. | Number of employees |
| Employees | 2,614 | at 2025-06-30 | Cons. | Number of employees |
| Employees | 2,517 | at 2024-06-30v | Cons. | Number of employees |
| Employees | 2,288 | at 2023-06-30v | Cons. | Number of employees |
| Employees | 2,182 | at 2022-06-30v | Cons. | Number of employees |
| Revenue | ¥3.0bn | 2025-07-01 → 2026-06-30 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2024-07-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥2.9bn | 2023-07-01 → 2024-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-07-01 → 2023-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2021-07-01 → 2022-06-30v | Standalone | Net sales (5-year summary) |
| Operating income | ¥367m | 2025-07-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | ¥265m | 2024-07-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | ¥542m | 2025-07-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥482m | 2024-07-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥707m | 2023-07-01 → 2024-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥968m | 2022-07-01 → 2023-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥998m | 2021-07-01 → 2022-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥287m | 2025-07-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥482m | 2024-07-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | ¥282m | 2025-07-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | ¥475m | 2024-07-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | ¥649m | 2023-07-01 → 2024-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.0bn | 2022-07-01 → 2023-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥932m | 2021-07-01 → 2022-06-30v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥25.5bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥26.1bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥26.0bn | at 2024-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥22.8bn | at 2023-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.9bn | at 2022-06-30v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥16.1bn | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥16.3bn | at 2025-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥9.3bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥9.9bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥9.9bn | at 2024-06-30v | Standalone | Net assets |
| Net assets / equity | ¥9.3bn | at 2023-06-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.6bn | at 2022-06-30v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥72m | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥180m | at 2025-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥12.66 | 2025-07-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.36 | 2024-07-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.55 | 2023-07-01 → 2024-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.27 | 2022-07-01 → 2023-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.56 | 2021-07-01 → 2022-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥12.64 | 2025-07-01 → 2026-06-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.33 | 2024-07-01 → 2025-06-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.43 | 2023-07-01 → 2024-06-30v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.12 | 2022-07-01 → 2023-06-30v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.48 | 2021-07-01 → 2022-06-30v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2025-07-01 → 2026-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2024-07-01 → 2025-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2023-07-01 → 2024-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-07-01 → 2023-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2021-07-01 → 2022-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥420.39 | at 2026-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥444.98 | at 2025-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥448.09 | at 2024-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥425.81 | at 2023-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥394.52 | at 2022-06-30v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 36.7% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.8% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2024-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2023-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.9% | 2025-07-01 → 2026-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2024-07-01 → 2025-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2023-07-01 → 2024-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2022-07-01 → 2023-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-07-01 → 2022-06-30v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 22,238,217 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,238,217 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,147,494 | at 2024-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,925,104 | at 2023-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,925,104 | at 2022-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 132 | at 2026-06-30 | Standalone | Number of employees |
| Employees | 93 | at 2025-06-30 | Standalone | Number of employees |
| Employees | 93 | at 2024-06-30v | Standalone | Number of employees |
| Employees | 90 | at 2023-06-30v | Standalone | Number of employees |
| Employees | 71 | at 2022-06-30v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-07-01 → 2026-06-30 | ¥232m |
| Reconciling Itemsreconciling | depreciation | 2025-07-01 → 2026-06-30 | ¥642m |
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2026-06-30 | −¥17m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2026-06-30 | −¥17m |
| Reconciling Itemsreconciling | segment assets | at 2026-06-30 | ¥32.4bn |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2026-06-30 | −¥8.5bn |
| Medical Equipment Salesreportable segment | capex | 2025-07-01 → 2026-06-30 | ¥844m |
| Medical Equipment Salesreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥750m |
| Medical Equipment Salesreportable segment | employees | at 2026-06-30 | 2161 pure |
| Medical Equipment Salesreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥296.0bn |
| Medical Equipment Salesreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥296.0bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥17m |
| Medical Equipment Salesreportable segment | segment assets | at 2026-06-30 | ¥78.5bn |
| Medical Equipment Salesreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥9.7bn |
| Nursing Welfarereportable segment | capex | 2025-07-01 → 2026-06-30 | ¥495m |
| Nursing Welfarereportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥535m |
| Nursing Welfarereportable segment | employees | at 2026-06-30 | 211 pure |
| Nursing Welfarereportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥6.3bn |
| Nursing Welfarereportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥6.3bn |
| Nursing Welfarereportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥15,000 |
| Nursing Welfarereportable segment | segment assets | at 2026-06-30 | ¥1.7bn |
| Nursing Welfarereportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥587m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-07-01 → 2026-06-30 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-07-01 → 2026-06-30 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-07-01 → 2026-06-30 | ¥302.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-07-01 → 2026-06-30 | ¥302.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥17m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-06-30 | ¥80.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-07-01 → 2026-06-30 | ¥10.3bn |
| Reconciling Itemsreconciling | capex | 2024-07-01 → 2025-06-30 | ¥475m |
| Reconciling Itemsreconciling | depreciation | 2024-07-01 → 2025-06-30 | ¥728m |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2025-06-30 | −¥22m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2025-06-30 | −¥22m |
| Reconciling Itemsreconciling | segment assets | at 2025-06-30 | ¥43.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2025-06-30 | −¥9.1bn |
| Medical Equipment Salesreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥1.9bn |
| Medical Equipment Salesreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥617m |
| Medical Equipment Salesreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥282.7bn |
| Medical Equipment Salesreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥282.7bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥22m |
| Medical Equipment Salesreportable segment | segment assets | at 2025-06-30 | ¥68.3bn |
| Medical Equipment Salesreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥10.4bn |
| Nursing Welfarereportable segment | capex | 2024-07-01 → 2025-06-30 | ¥433m |
| Nursing Welfarereportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥528m |
| Nursing Welfarereportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥6.0bn |
| Nursing Welfarereportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥6.0bn |
| Nursing Welfarereportable segment | segment assets | at 2025-06-30 | ¥1.5bn |
| Nursing Welfarereportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥516m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-07-01 → 2025-06-30 | ¥2.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-07-01 → 2025-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-07-01 → 2025-06-30 | ¥288.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-07-01 → 2025-06-30 | ¥288.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥22m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-06-30 | ¥69.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-07-01 → 2025-06-30 | ¥11.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,677
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | -1820524000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 1450000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -1619949000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -1015998000 | JPY |
| Redemption of bonds fin cf | Prior1YearDuration | － | JPY |
| Redemption of bonds fin cf | CurrentYearDuration | -8000000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YearDuration | 71815000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYearDuration | － | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -85796000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -117867000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -33000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -464889000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -443903000 | JPY |
| Proceeds from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YearDuration | － | JPY |
| Proceeds from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYearDuration | 9000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -3468819000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -3397326000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 1037578000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -4287314000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 13544776000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 14320367000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YearDuration | 42959000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYearDuration | － | JPY |
| Decrease in cash and cash equivalents resulting from change of fiscal term of subsidiaries cf | Prior1YearDuration | -304947000 | JPY |
| Decrease in cash and cash equivalents resulting from change of fiscal term of subsidiaries cf | CurrentYearDuration | － | JPY |
| Cash and cash equivalents | Prior1YearInstant | 14320367000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 10033053000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 15 | |
| Electronically recorded monetary claims discounted | Prior1YearInstant | 931609000 | JPY |
| Electronically recorded monetary claims discounted | CurrentYearInstant | 1066309000 | JPY |
| Notes receivable trade | Prior1YearInstant | 102011000 | JPY |
| Notes receivable trade | CurrentYearInstant | 6678000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 54622046000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 58559124000 | JPY |
| Electronically recorded monetary claims | Prior1YearInstant | 3264793000 | JPY |
| Electronically recorded monetary claims | CurrentYearInstant | 3452321000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E22995-000MedicalEquipmentSalesReportableSegmentsMember | 282688195000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E22995-000NursingWelfareReportableSegmentsMember | 6001143000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 288689338000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 288689338000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E22995-000MedicalEquipmentSalesReportableSegmentsMember | 21903000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E22995-000NursingWelfareReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 21903000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -21903000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E22995-000MedicalEquipmentSalesReportableSegmentsMember | 282710099000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E22995-000NursingWelfareReportableSegmentsMember | 6001143000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |